Non-muscle Invasive Bladder Cancer
📧 Sign up to get email alerts when something new happens for Non-muscle Invasive Bladder Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) [Phase 3]
Phase 3 clinical trial evaluating TAR-200 with cetrelimab or TAR-200 alone versus intravesical BCG in BCG-naïve high-risk non-muscle invasiv…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) [Phase 3]
Phase 3 trial comparing TAR-200 to intravesical chemotherapy in patients with recurrent high-risk non-muscle-invasive bladder cancer after B…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer [Phase 3]
Phase 3 trial comparing ANKTIVA plus BCG versus BCG monotherapy in high-grade non-muscle invasive bladder cancer (BCG-naïve or BCG-exposed).
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer [Phase 2]
TYRA-300 is being investigated in a Phase 2 trial for FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer; the stu…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
The document announces the recruitment status for a clinical evaluation of BCDx to monitor recurrence in non-muscle invasive bladder cancer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin [Phase 2]
Phase 2 clinical trial update for Cretostimogene in non-muscle-invasive bladder cancer unresponsive to BCG, currently recruiting by Lepu Bio…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer [Phase 2]
This update summarizes a Phase 2 study of oral erdafitinib in patients with recurrent non-muscle invasive bladder cancer, including FGFR3-mu…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
This clinical trial update reports that recruitment is ongoing for a study comparing intravesical therapy and surgical options for bladder c…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer [Phase 1]
Phase 1 study of PF-08052667 in non-muscle invasive bladder cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance [Phase 2]
Phase 2 clinical trial evaluating urine testing as a non-invasive surveillance method to replace cystoscopy in non-muscle-invasive bladder c…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer [Phase 3]
Phase 3 trial evaluating intravesical nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy for high-grade BCG…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC [Phase 2]
Phase 2 clinical trial evaluating intravesical gemcitabine and docetaxel for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer;…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Holmium Laser En-Bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle- Invasive Bladder Cancer [NA]
A completed clinical trial comparing holmium laser en-bloc resection versus conventional transurethral resection of bladder tumors for non-m…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer [Phase 1]
A Phase 1, open-label trial evaluating Belzupacap Sarotalocan (AU-011) for non-muscle-invasive bladder cancer is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
Expanded-access treatment program for the investigational gene therapy Cretostimogene Grenadanorepvec to treat non-muscle-invasive bladder c…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
A clinical trial update focusing on tumor budding and T1 sub-staging in urothelial bladder cancer; recruitment is not yet started.
-
CLINICAL_TRIALS other · 2026-04-14Clinical Trial Update: Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer [Phase 3]
Phase 3 trial evaluating durvalumab in combination with BCG versus standard BCG therapy for non-muscle-invasive bladder cancer is currently …
-
CLINICAL_TRIALS approval · 2026-04-13Clinical Trial Update: Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
TAR-200 has been approved for marketing for non-muscle invasive bladder cancer, and the update notes a pre-approval expanded-access program …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy [Phase 2]
Phase 2 trial evaluating TAR-200 alone or in combination with cetrelimab, and cetrelimab alone, in non-muscle invasive bladder cancer unresp…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) [Phase 3]
This clinical trial update covers a Phase 3 study evaluating TAR-200 with or without cetrelimab versus intravesical BCG in patients with hig…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer [Phase 2]
A Phase 2 study is testing pembrolizumab added to intravesical gemcitabine for BCG-unresponsive non-muscle invasive bladder cancer, with the…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) [Phase 3]
Phase 3 study comparing TAR-200 with intravesical chemotherapy in patients with recurrent high-risk non-muscle-invasive bladder cancer follo…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
A study to evaluate real-world use and outcomes of TAR-200 for non-muscle-invasive bladder cancer in the United States is currently recruiti…
-
CLINICAL_TRIALS other · 2026-04-13Clinical Trial Update: A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer [Phase 3]
A Phase 3 study evaluating TAR-210 versus single-agent intravesical therapy for non-muscle invasive bladder cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer [Phase 1, Phase 2]
This clinical trial update describes an intravesical delivery system delivering erdafitinib for localized, non-muscle-invasive bladder cance…